San Francisco, California-- (Newsfile Corp. - March 17, 2025) - Novo Nordisk A/S (NYSE: NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the ...

Novo Nordisk (NVO) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Key Takeaways Novo Nordisk shares gained Monday as the company said it would present new data on the ability of semaglutide, ...

NEW YORK, NY / ACCESS Newswire / March 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.

Novo Nordisk (NVO) ended the recent trading session at $75.89, demonstrating a +1.47% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily ...

Novo Nordisk A/S (NYSE: NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects ...

For Novo Nordisk A/S investors (NVO), things couldn't have gotten to a worse start this week. Just when the market was preparing for a bottom, as NVO has been consolidating constructively over the ...

Novo Nordisk rejoined the ABPI after a two-year suspension linked to promotional concerns. Audits confirmed compliance with ...

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

Proficio Capital Partners LLC acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) in the 4th quarter, ...

Novo Nordisk (NVO) ended the recent trading session at $75.89, demonstrating a +1.47% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily loss of ...